Drug Profile
Research programme: photodynamic therapy for cancer - Bluepharma/Universidade de Coimbra
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Bluepharma; Universidade de Coimbra
- Class
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Portugal
- 09 Jan 2014 Preclinical trials in Cancer in Portugal (unspecified route)
- 08 Dec 2010 Luzitin licensed patents by Bluepharma and Universidade de Coimbra for further development of the lead candidate